Seeking Alpha

Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it...

Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it widespread rights for kidney disease treatment KAI-4169. As part of the agreement between the firms, Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to the transaction closing.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)